We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Potential New Sources of Stem Cells

By Biotechdaily staff writers
Posted on 24 May 2002
If proven viable, two new sources of stem cells being investigated would avoid the current controversy surrounding the use of embryonic stem cells for treating disease.

Defective embryos may be one new source of stem cells, according to scientists from the Wellcome Cancer Research Institute at Cambridge University (UK). More...
Dr. John Gurdon and colleagues discovered that defective or abnormal cloned frog embryos produced normal stem cells, which can be manipulated to form any kind of cell in the body. Many of the human embryos that result from in vitro fertilization attempts are also abnormal and are discarded. The scientists believe that some of these may produce normal stem cells.

Another potential source of stem cells under investigation is the human umbilical cord. A neuroscientist at the University of South Florida (USF, Tampa, USA), Tanja Zigova, Ph.D., has been awarded a US$1.3 million grant to study whether stem cells from human umbilical cord blood (HUCB) can treat age-related mental decline and neurodegenerative diseases. Studies suggest that HUCB may be a more readily available source of therapeutic cells for treating Parkinson's or Alzheimer's disease.

Cord blood cells include a significant number of stem cells. Researchers at the USF Center for Aging and Brain Repair have shown that these cells can be reprogrammed to become immature nerve cells. They have also demonstrated that HUCB cells transplanted into the developing brains of neonatal rats begin to look like nerve cells and express certain proteins found only in neurons and glial cells. The new USF study will use a model of aging rats to test which growth and nutritional factors best prompt malleable HUBC cells to become specific types of neurons, to determine if the age of transplant recipients affects the ability of HUBC cells to grow and differentiate, and to determine if HUCB-derived cells transplanted into the brains of aging rats can reverse or slow age-related declines in learning and memory.

"Our ultimate goal is to find out how to turn enough of them into specialized neurons that would read specific cues from the brain, migrate where we want them to go, and produce the types of neurotransmitters that must be replenished to restore nerve function,” said Dr. Zigova, principal investigator.




Related Links:
University of South Florida

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Automatic Western Blot Analyzer
Tenfly Phoenix Blot Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.